Effects of Cyclooxygenase-2 Inhibition on Serum and Tumor Gastrins and Expression of Apoptosis-Related Proteins in Colorectal Cancer

[1]  E. Solary,et al.  Cellular localisation of Survivin: impact on the prognosis in colorectal cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[2]  Cristina Vassalle,et al.  Gastrin promotes human colon cancer cell growth via CCK‐2 receptor‐mediated cyclooxygenase‐2 induction and prostaglandin E2 production , 2005, British journal of pharmacology.

[3]  Qiang Liu,et al.  Expression of survivin and its significance in colorectal cancer. , 2004, World journal of gastroenterology.

[4]  S. Watson,et al.  The role of gastrin in colorectal carcinogenesis. , 2004, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[5]  J. Lord,et al.  Cytotoxic ribosome-inactivating lectins from plants. , 2004, Biochimica et biophysica acta.

[6]  R. Peek.  Prevention of colorectal cancer through the use of COX-2 selective inhibitors , 2004, Cancer Chemotherapy and Pharmacology.

[7]  S. Fenwick,et al.  The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. , 2003, Gastroenterology.

[8]  A. Barkun,et al.  The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. , 2003, Gastroenterology.

[9]  J. Rehfeld,et al.  Progastrin and Cyclooxygenase-2 in Colorectal Cancer , 2002, Digestive Diseases and Sciences.

[10]  M. Wolfe,et al.  COX-2 selective inhibition reverses the trophic properties of gastrin in colorectal cancer , 2002, British Journal of Cancer.

[11]  E. Hahn,et al.  Helicobacter pylori infection, gastrin, cyclooxygenase-2, and apoptosis in colorectal cancer , 2001, International Journal of Colorectal Disease.

[12]  A. Gilliam,et al.  G17DT - a new weapon in the therapeutic armoury for gastrointestinal malignancy , 2001, Expert opinion on biological therapy.

[13]  A. Smith,et al.  Gastrin and Colorectal Cancer , 2000 .

[14]  R. Langenbach,et al.  Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. , 2000, Cancer research.

[15]  P. Tak,et al.  The Effect of a T Cell-Specific NF-κB Inhibitor on In Vitro Cytokine Production and Collagen-Induced Arthritis1 , 2000, The Journal of Immunology.

[16]  G. Crosthwaite,et al.  Proton pump inhibitors for Barrett's oesophagus , 2000, Gut.

[17]  T. Wang,et al.  Progastrin expression predisposes mice to colon carcinomas and adenomas in response to a chemical carcinogen. , 2000, Gastroenterology.

[18]  J. Rehfeld,et al.  Closing the gastrin loop in pancreatic carcinoma , 2000, Cancer.

[19]  S. Kelly,et al.  Plasma levels of progastrin but not amidated gastrin or glycine extended gastrin are elevated in patients with colorectal carcinoma , 2000, Gut.

[20]  F. Marks,et al.  Cellular localization of cyclo-oxygenase isozymes in Crohn’s disease and colorectal cancer , 1999, International Journal of Colorectal Disease.

[21]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[22]  R. Gaynor,et al.  Sulindac Inhibits Activation of the NF-κB Pathway* , 1999, The Journal of Biological Chemistry.

[23]  B. Rump,et al.  Helicobacter pylori and the Risk of Colonic Adenomas , 1999, Digestion.

[24]  R. Pounder,et al.  Expression and processing of gastrin in hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma. , 1999, Journal of hepatology.

[25]  C. Paraskeva,et al.  Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  I. Lehman.  Eukaryotic DNA Repair Minireview Series* , 1997, The Journal of Biological Chemistry.

[27]  P. de Micco,et al.  The human gastrin/cholecystokinin receptors: type B and type C expression in colonic tumors and cell lines. , 1997, Life sciences.

[28]  J. Morrow,et al.  Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. , 1997, The Journal of clinical investigation.

[29]  J. Lehmann,et al.  Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.

[30]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[31]  S. Konturek,et al.  New approach to 13C-urea breath test: capsule-based modification with low-dose of 13C-urea in the diagnosis of Helicobacter pylori infection. , 1996, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[32]  M. Schuler.  Aspirin and the risk of colorectal cancer in women. , 1996, The New England journal of medicine.

[33]  G. Ciccotosto,et al.  Expression, processing, and secretion of gastrin in patients with colorectal carcinoma. , 1995, Gastroenterology.

[34]  D. Alberts,et al.  Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. , 1995, Cancer research.

[35]  B. Rigas,et al.  Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. , 1995, The Journal of clinical investigation.

[36]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[37]  E. Rimm,et al.  Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professionals , 1994, Annals of Internal Medicine.

[38]  I. Sobhani,et al.  Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. , 1993, Gastroenterology.

[39]  R. Koski,et al.  Expression of the gastrin gene in the normal human colon and colorectal adenocarcinoma. , 1993, Cancer research.

[40]  G. Baldwin,et al.  Measurement of gastrin and transforming growth factor alpha messenger RNA levels in colonic carcinoma cell lines by quantitative polymerase chain reaction. , 1992, Cancer research.

[41]  M. Thun,et al.  Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.

[42]  A. Zauber,et al.  The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. , 1990, Gastroenterology.

[43]  A. Zauber,et al.  The National Polyp Study , 1990 .

[44]  O. Skraastad.  [Dietary factors and risk of colon cancer]. , 1990, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[45]  L. Johnson.  Regulation of gastrointestinal mucosal growth , 1979, World Journal of Surgery.

[46]  J. Kral,et al.  The NF-κB/IκB signaling system: A molecular target in breast cancer therapy , 2005 .

[47]  F. Sinicrope,et al.  Role of cyclooxygenase-2 in colorectal cancer , 2004, Cancer and Metastasis Reviews.

[48]  D. Chang,et al.  A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[50]  T. Wang,et al.  The gastrins: their production and biological activities. , 2001, Annual review of physiology.

[51]  S. Watson,et al.  Review article: gastrin and colorectal cancer. , 2000, Alimentary pharmacology & therapeutics.

[52]  R. Gaynor,et al.  Sulindac inhibits activation of the NF-kappaB pathway. , 1999, The Journal of biological chemistry.

[53]  B. Rump,et al.  Helicobacter pylori and the risk of colonic adenomas. Colorectal Adenoma Study Group. , 1999, Digestion.

[54]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[55]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.